News

Dividing AAV According to Antibodies Provides No Further Benefit for Prognosis, Study Reports

Dividing ANCA-associated vasculitis (AAV) into subgroups defined by type of antibodies does not provide additional value for clinical prognosis, according to recent research. The study, “Clinical impact of subgrouping ANCA-associated vasculitis according to antibody specificity beyond the clinicopathological classification,” appeared in the journal Rheumatology. Different…

Rise in MPO-ANCA Antibodies After Remission May Predict Relapse

Among ANCA-associated vasculitis patients in remission — particularly those with manifestations in their kidneys — the reappearance of MPO-ANCA antibodies may be a sign of disease relapse, a study suggests. The study, “Association Between Reappearance of Myeloperoxidase-Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis,” was…

Antibody Fragment May Be Used to Treat ANCA Vasculitis, Study Reports

A piece of an antibody targeting a protein involved in cholesterol transport and metabolism might be an effective treatment for anti-neutrophil cytoplasmic autoantibodies (ANCA) vasculitis, a study suggests. The study, “Efficacy of a recombinant single-chain fragment variable region, VasSF, as a new drug for vasculitis,” was published in …

Study: IV Methylprednisolone Doesn’t Benefit, May Harm AAV Patients

Adding intravenous methylprednisolone pulses to standard treatment for inducing remission in severe cases of ANCA-associated vasculitis does not confer clinical benefits and increases the risk of infection and diabetes, a study suggests. The study, “Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective…